U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
The U.S. Food and Drug Administration on Friday approved the country's first gene-editing treatment, Casgevy, for use in patients with sickle cell disease.The approval comes about a decade after the discovery of CRISPR technology for…